ArticleBMC cancer2026
High-risk cytogenetic abnormalities impact the cytological and clinical behavior of core binding factor acute myeloid leukemia: a case-control study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite its classification as acute myeloid leukemia (AML) with favorable prognosis, core binding factor AML (CBF-AML) with t(8;21)/inv(16) exhibits clinical heterogeneity with varying remission and relapse rates. Newly emerging data suggest a modulatory effect of additional cytogenetic abnormalities on the clinical behavior of CBF-AML, with high-risk anomalies negatively affecting survival.
methodsAiming at validating these observations, we compare the pathological and clinical characteristics of CBF-AML patients with high-risk additional cytogenetic abnormalities (HR-ACAs) to CBF-AML without HR-ACAs.
resultsThe 14-year retrospective review of the laboratory and clinical data of 535 AML patients diagnosed at our institution shows that 37% of CBF-AML patients carry at least one secondary cytogenetic abnormality. HR-ACAs, primarily complex karyotypes, constituted 38% of secondary abnormalities. Interestingly, patients with HR-ACAs more frequently presented with cytopenia, and exhibited more aggressive clinical courses. The detection of HR-ACAs was found to be associated with higher relapse rates (50% vs. 18%;p = 0.006), a greater requirement for stem cell transplantation (89% vs. 27%;p = 0.001), and higher death rates (63% vs. 17%;p = 0.008).
conclusionThese results indicate that the presence of HR-ACAs impacts the cytological and clinical features of CBF-AML. This entity thus deserves distinct considerations for risk stratification and therapeutic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.